Delayed release citraconic acid - Cycle Pharmaceuticals
Alternative Names: BAFIERTAM; Delayed release monomethyl fumarate - Cycle PharmaceuticalsLatest Information Update: 21 Jan 2025
At a glance
- Originator Banner Life Sciences
- Developer Cycle Pharmaceuticals
- Class Fumarates; Maleates; Small molecules
- Mechanism of Action NF-E2-related factor 2 stimulants; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple sclerosis
Most Recent Events
- 13 Jan 2025 Banner Life Sciences has been acquired and merged into Cycle Pharmaceuticals
- 27 Aug 2021 Banner Life Sciences completes a bioequivalence phase I trial in healthy volunteers in USA (PO, Capsules) in May 2021 (NCT05181215)
- 14 May 2021 Banner Life Sciences initiates enrolment in a bioequivalence phase I trial in healthy volunteers in USA (PO, Capsules) in May 2021 (NCT05181215)